Spots Global Cancer Trial Database for biliary tract neoplasms
Every month we try and update this database with for biliary tract neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers | NCT04910386 | Biliary Tract N... | Envafolimab plu... Gemcitabine&Cis... | 18 Years - | 3D Medicines | |
| Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents | NCT01315522 | Biliary Tract N... Jaundice, Obstr... | ComVi stent Uncovered SEMS | 20 Years - | Seoul National University Hospital | |
| The Effect of Individualized Precision Therapy Programs in Patients With BTC | NCT02943031 | Biliary Tract N... | Individualized ... | 18 Years - | RenJi Hospital | |
| Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | NCT03101566 | Biliary Tract N... | Gemcitabine Cisplatin Ipilimumab Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing | NCT05520788 | Hepatocellular ... Biliary Tract C... | precise medicin... | 18 Years - | Tongji Hospital | |
| A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy | NCT00359320 | Pancreatic Neop... Biliary Tract N... Pancreatitis, C... Duodenal Neopla... | pancreaticojeju... | 18 Years - | Thomas Jefferson University | |
| Radiofrequency Ablation for Malignant Biliary Obstruction | NCT01758341 | Biliary Tract N... | Endoscopic radi... Endoscopic retr... HabibTM EndoHPB... | 18 Years - | Medical University of Vienna | |
| Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer | NCT00487851 | Pancreatic Neop... Biliary Tract N... Duodenal Neopla... | surgery endoscopic stra... | - | Karolinska Institutet | |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | NCT04976634 | Carcinoma, Hepa... Colorectal Neop... Pancreatic Duct... Biliary Tract N... Endometrial Neo... Esophageal Neop... | Pembrolizumab Belzutifan Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Precise Treatment in Hepatobiliary Cancers (PTHBC) | NCT02715089 | Liver Neoplasms Biliary Tract N... Hepatobiliary N... | Precise treatme... | 18 Years - 65 Years | Peking Union Medical College Hospital | |
| Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC | NCT03478488 | Biliary Tract N... | KN035 plus Gemc... Gemcitabine & o... | 18 Years - | 3D Medicines | |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | NCT01950572 | Mesothelioma Thymoma Pancreatic Neop... Biliary Tract N... Stomach Neoplas... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) | NCT06375967 | Malignant Bilia... Biliary Tract N... Pancreatic Canc... | Endoscopic bili... Lumen-apposing ... Lumen-apposing ... | 18 Years - 100 Years | Hospital Universitari de Bellvitge | |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | NCT04579380 | Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ... | tucatinib trastuzumab fulvestrant | 18 Years - | Seagen Inc. | |
| EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) | NCT06375967 | Malignant Bilia... Biliary Tract N... Pancreatic Canc... | Endoscopic bili... Lumen-apposing ... Lumen-apposing ... | 18 Years - 100 Years | Hospital Universitari de Bellvitge | |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | NCT01950572 | Mesothelioma Thymoma Pancreatic Neop... Biliary Tract N... Stomach Neoplas... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer | NCT05190575 | Biliary Tract N... | TST001 | 18 Years - | Shanghai Zhongshan Hospital | |
| The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer | NCT00268840 | Pancreatic Neop... Biliary Tract N... | Docetaxel Gemcitabine | 18 Years - 60 Years | ARCAGY/ GINECO GROUP | |
| EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) | NCT06375928 | Malignant Bilia... Pancreatic Canc... Biliary Tract N... | Endoscopic bili... Self-expandable... Lumen-apposing ... | 18 Years - | Hospital Universitari de Bellvitge | |
| The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer | NCT00268840 | Pancreatic Neop... Biliary Tract N... | Docetaxel Gemcitabine | 18 Years - 60 Years | ARCAGY/ GINECO GROUP | |
| A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | NCT02821754 | Biliary Tract N... Liver Cancer Hepatocellular ... Cholangiocarcin... Bile Duct Cance... | Durvalumab Tremelimumab Trans-arterial ... Radiofrequency ... Cryoablation | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) | NCT06375954 | Malignant Bilia... Pancreatic Canc... Biliary Tract N... | Endoscopic bili... Self-expandable... Lumen-apposing ... | 18 Years - | Hospital Universitari de Bellvitge | |
| Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents | NCT01315522 | Biliary Tract N... Jaundice, Obstr... | ComVi stent Uncovered SEMS | 20 Years - | Seoul National University Hospital | |
| Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer | NCT06276153 | Biliary Tract D... Gallbladder Can... Gallbladder Neo... | no intervention... | 18 Years - 74 Years | RenJi Hospital | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer | NCT03406299 | Biliary Tract N... | Tegafur Leucovorin Oxaliplatin Gemcitabine Cisplatin | 20 Years - | National Health Research Institutes, Taiwan | |
| A Study of DB-1303 in Advanced/Metastatic Solid Tumors | NCT05150691 | HER2-positive A... | DB-1303 Pertuzumab Inje... Ritonavir Itraconazole | 18 Years - | DualityBio Inc. | |
| Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics | NCT04584008 | Biliary Tract N... Gastric Cancer Esophageal Squa... Colorectal Canc... Gastrointestina... Pancreatic Canc... Neuroendocrine ... Unknown Primary... Digestive Cance... | FGFR Inhibitor,... Other Therapy | 18 Years - | Peking University | |
| Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction | NCT02255669 | Biliary Tract N... | partially cover... fully covered S... | 19 Years - | Samsung Medical Center | |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | NCT05896956 | Biliary Tract D... Gallbladder Can... Extrahepatic Bi... Intrahepatic Ch... Biliary Tract N... Gall Stone | no intervention... | 18 Years - 74 Years | RenJi Hospital | |
| Primary Hepatobiliary Cancer Cohort of Central China | NCT05520801 | Hepatocellular ... Biliary Tract N... | 18 Years - | Tongji Hospital | ||
| LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent | NCT04595058 | Biliary Obstruc... Pancreatic Canc... Biliary Tract N... | Double pigtail ... Lumen-apposing ... | 18 Years - | Hospital Universitari de Bellvitge | |
| Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT) | NCT05723705 | Liver Diseases Liver Neoplasm Liver Cancer Liver Metastase... Biliary Tract C... Biliary Tract N... Biliary Tract D... | European Multic... | 18 Years - | Amsterdam UMC, location VUmc | |
| Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents | NCT01315522 | Biliary Tract N... Jaundice, Obstr... | ComVi stent Uncovered SEMS | 20 Years - | Seoul National University Hospital | |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | NCT03093870 | Biliary Tract C... | Varlitinib Capecitabine Placebo (for Va... | - | ASLAN Pharmaceuticals | |
| Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics | NCT04584008 | Biliary Tract N... Gastric Cancer Esophageal Squa... Colorectal Canc... Gastrointestina... Pancreatic Canc... Neuroendocrine ... Unknown Primary... Digestive Cance... | FGFR Inhibitor,... Other Therapy | 18 Years - | Peking University | |
| Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy | NCT01731821 | Pancreatic Neop... Biliary Tract N... Pancreatitis, C... Duodenal Neopla... | pancreaticojeju... | 18 Years - 80 Years | Fudan University | |
| Endoscopic Therapy of Malignant Bile Duct Strictures | NCT01543607 | Obstruction of ... Biliary Tract C... Biliary Tract N... | Radiofrequency ... | 18 Years - | Massachusetts General Hospital | |
| The Diagnostic Value of Combinatory EUS and ERCP in Unclear Lesions | NCT03504293 | Neoplasms Biliary Strictu... Biliary Tract N... Biliary Tract D... | Combinatory EUS... | 18 Years - | Sahlgrenska University Hospital, Sweden | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope | NCT05429203 | Biliary Disease Pancreatic Dise... Choledocholithi... Biliary Obstruc... Biliary Tract N... Pancreatic Neop... | Duodenoscope wi... Conventional du... | 18 Years - | Stanford University | |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | NCT03093870 | Biliary Tract C... | Varlitinib Capecitabine Placebo (for Va... | - | ASLAN Pharmaceuticals | |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | NCT03111732 | Biliary Tract N... Cholangiocarcin... Bile Duct Cance... Liver Cancer Gallbladder Can... | Pembrolizumab (... Oxaliplatin Capecitabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent | NCT04595058 | Biliary Obstruc... Pancreatic Canc... Biliary Tract N... | Double pigtail ... Lumen-apposing ... | 18 Years - | Hospital Universitari de Bellvitge | |
| Precise Treatment in Hepatobiliary Cancers (PTHBC) | NCT02715089 | Liver Neoplasms Biliary Tract N... Hepatobiliary N... | Precise treatme... | 18 Years - 65 Years | Peking Union Medical College Hospital | |
| Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer | NCT02558959 | Biliary Tract N... | Irinotecan Capecitabine | 18 Years - 75 Years | Zhejiang University | |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | NCT01950572 | Mesothelioma Thymoma Pancreatic Neop... Biliary Tract N... Stomach Neoplas... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer | NCT05190575 | Biliary Tract N... | TST001 | 18 Years - | Shanghai Zhongshan Hospital | |
| Radiofrequency Ablation for Malignant Biliary Obstruction | NCT01758341 | Biliary Tract N... | Endoscopic radi... Endoscopic retr... HabibTM EndoHPB... | 18 Years - | Medical University of Vienna | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) | NCT06375954 | Malignant Bilia... Pancreatic Canc... Biliary Tract N... | Endoscopic bili... Self-expandable... Lumen-apposing ... | 18 Years - | Hospital Universitari de Bellvitge | |
| RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction | NCT00980889 | Biliary Tract N... Pancreatic Neop... Stent Occlusion | Steel Nitinol | 20 Years - | Stockholm South General Hospital | |
| Apatinib for Advanced Biliary Carcinoma | NCT03427242 | Biliary Tract N... | Apatinib | 18 Years - 70 Years | Fudan University | |
| EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) | NCT06375928 | Malignant Bilia... Pancreatic Canc... Biliary Tract N... | Endoscopic bili... Self-expandable... Lumen-apposing ... | 18 Years - | Hospital Universitari de Bellvitge | |
| Tremelimumab With Chemoembolization or Ablation for Liver Cancer | NCT01853618 | Heptocellular C... Biliary Tract N... Liver Cancer Hepatocellular ... Biliary Cancer | Tremelimumab RFA TACE Cryoablation | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Primary Hepatobiliary Cancer Cohort of Central China | NCT05520801 | Hepatocellular ... Biliary Tract N... | 18 Years - | Tongji Hospital | ||
| Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction | NCT02255669 | Biliary Tract N... | partially cover... fully covered S... | 19 Years - | Samsung Medical Center | |
| Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy | NCT01695447 | Pancreatic Neop... Biliary Tract N... | duct-to-mucosa invagination Internal stent | 18 Years - 80 Years | Zhejiang University | |
| Primary Hepatobiliary Cancer Cohort of Central China | NCT05520801 | Hepatocellular ... Biliary Tract N... | 18 Years - | Tongji Hospital | ||
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | NCT03801083 | Biliary Tract C... Cholangiocarcin... Biliary Tract N... | Tumor Infiltrat... | 18 Years - 75 Years | University of Pittsburgh | |
| TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer | NCT05190575 | Biliary Tract N... | TST001 | 18 Years - | Shanghai Zhongshan Hospital | |
| RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction | NCT00980889 | Biliary Tract N... Pancreatic Neop... Stent Occlusion | Steel Nitinol | 20 Years - | Stockholm South General Hospital | |
| Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers | NCT00939848 | Biliary Tract N... | gemcitabine cisplatin Placebo cisplatin cediranib gemcitabine | 18 Years - | University College, London | |
| A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | NCT04856761 | Biliary Tract N... Recurrence Cholangiocarcin... Gall Bladder Ca... | S-1 Capecitabine | 18 Years - 75 Years | Fudan University | |
| Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers | NCT00939848 | Biliary Tract N... | gemcitabine cisplatin Placebo cisplatin cediranib gemcitabine | 18 Years - | University College, London | |
| A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up | NCT05237193 | Biliary Tract N... Pancreatic Carc... Gallbladder Can... Pancreatic Head... | The level of CI... | 18 Years - | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| Endoscopic Stenting of Gastrointestinal Cancer | NCT00422409 | Gastrointestina... Biliary Tract N... | Endoscopic sten... | 18 Years - | Oslo University Hospital | |
| Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors | NCT04010071 | Hepatobiliary N... Liver Neoplasm Biliary Tract N... | axitinib plus t... | 18 Years - | Peking Union Medical College Hospital | |
| The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer | NCT02809898 | Biliary Tract N... | surgery or biop... | 18 Years - 70 Years | RenJi Hospital | |
| A Study of DB-1303 in Advanced/Metastatic Solid Tumors | NCT05150691 | HER2-positive A... | DB-1303 Pertuzumab Inje... Ritonavir Itraconazole | 18 Years - | DualityBio Inc. | |
| Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer | NCT03231176 | Biliary Tract C... | Varlitinib Capecitabine | 18 Years - 99 Years | ASLAN Pharmaceuticals | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | NCT04956640 | Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N... | LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin | 18 Years - | Eli Lilly and Company | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | NCT03801083 | Biliary Tract C... Cholangiocarcin... Biliary Tract N... | Tumor Infiltrat... | 18 Years - 75 Years | University of Pittsburgh | |
| Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers | NCT04910386 | Biliary Tract N... | Envafolimab plu... Gemcitabine&Cis... | 18 Years - | 3D Medicines | |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | NCT04579380 | Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ... | tucatinib trastuzumab fulvestrant | 18 Years - | Seagen Inc. | |
| Evolution® Biliary Stent System Clinical Study | NCT01962168 | Biliary Tract N... Neoplasms Gastrointestina... Digestive Syste... Biliary Tract Stents | Evolution® Bili... | 18 Years - | Cook Group Incorporated | |
| Transparent Cap-assisted SpyGlass for Biliary Stricture | NCT05320497 | Bile Duct Stric... Endoscopic Retr... Biliary Disease Biliary Tract N... | Transparent cap | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer | NCT01242605 | Biliary Tract N... Cholangiocarcin... Gallbladder Neo... | selumetinib gemcitabine cisplatin | 18 Years - | University College, London |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
